留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

阿扎胞苷联合GemOx方案治疗母细胞性浆细胞样树突状细胞肿瘤一例

陈晓君 刘彦权 胡晓梅 黄素蓉 沈建箴

陈晓君, 刘彦权, 胡晓梅, 黄素蓉, 沈建箴. 阿扎胞苷联合GemOx方案治疗母细胞性浆细胞样树突状细胞肿瘤一例[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0465
引用本文: 陈晓君, 刘彦权, 胡晓梅, 黄素蓉, 沈建箴. 阿扎胞苷联合GemOx方案治疗母细胞性浆细胞样树突状细胞肿瘤一例[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0465
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen. Azacitidine Combined with GemOx Regimen in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0465
Citation: CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen. Azacitidine Combined with GemOx Regimen in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0465

阿扎胞苷联合GemOx方案治疗母细胞性浆细胞样树突状细胞肿瘤一例

doi: 10.12290/xhyxzz.2021-0465
基金项目: 

国家自然科学基金(81300428);福建省血液医学中心建设项目(闽卫医政[2017]171号);国家及福建省重点专科临床重点专科建设项目(闽卫医函[2011]1018号、闽卫科教[2012]149号)

详细信息
    通讯作者:

    沈建箴,电话:0591-83357896,E-mail:doctorsjz@163.com

  • 中图分类号: R552;R733

Azacitidine Combined with GemOx Regimen in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Funds: 

National Natural Science Foundation of China(81300428)

  • 摘要: 母细胞性浆细胞样树突状细胞肿瘤(blastic plasmacytoid dendriticcell neoplasm,BPDCN)是一种来源于浆细胞样树突状细胞前体细胞、高度恶性的血液系统肿瘤。原发于鼻腔的BPDCN临床极为罕见,易误诊、漏诊,目前关于BPDCN的治疗,国内外尚无标准方案。本文报道1例原发于鼻腔的BPDCN患者,在采用阿扎胞苷联合GemOx方案治疗后病情得到显著控制、临床症状改善明显。笔者通过对该患者的临床诊疗过程进行分析与探讨,以期提高临床医师对罕见BPDCN的认识。
  • [1] Sweet K. Blastic plasmacytoid dendritic cell neoplasm:diagnosis, manifestations, and treatment[J].Curr Opin Hematol,2020,27:103-107.
    [2] Venugopal S, Zhou S, El Jamal SM, et al. Blastic plasmacytoid dendritic cell neoplasm-current insights[J].Clin Lymphoma Myeloma Leuk, 2019,19:545-554.
    [3] Deconinck E, Petrella T, Garnache Ottou F. Blastic plasmacytoid dendritic cell neoplasm:clinical presentation and diagnosis[J].Hematol Oncol Clin North Am, 2020,34:491-500.
    [4] Kim MJ, Nasr A, Kabir B, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm:a systematic literature review[J].J Pediatr Hematol Oncol,2017,39:528-537.
    [5] Li Y, Sun V, Sun W, et al. Blastic plasmacytoid dendritic cell neoplasm in children[J]. Hematol Oncol Clin North Am, 2020,34:601-612.
    [6] Garnache-Ottou F, Vidal C, Biichlé S, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients[J]. Blood Adv, 2019,3:4238-4251.
    [7] Sakamoto K, Takeuchi K. Cytogenetics of blastic plasmacytoid dendritic cell neoplasm:chromosomal rearrangements and DNA copy-number alterations[J].Hematol Oncol Clin North Am, 2020,34:523-538.
    [8] Pagano L, Valentini CG, Grammatico S,et al. Blastic plasmacytoid dendritic cell neoplasm:diagnostic criteria and therapeutical approaches[J].Br J Haematol,2016,174:188-202.
    [9] Kerr D 2nd, Zhang L, Sokol L. Blastic Plasmacytoid Dendritic Cell Neoplasm[J].Curr Treat Options Oncol,2019,20:9.
    [10] Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm[J]. Hematology Am Soc Hematol Educ Program,2016,2016:16-23. o acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens[J]. Leuk Lymphoma, 2019,60:1030-1035.
    [11] Rai S, Singh S, Gupta R. Prognostic significance of CD56 and CD7 in acute myeloid leukaemia and their outcome[J]Am J Blood Res, 2020,10:109-117.
    [12] Sapienza MR, Pileri S. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm:DNA Mutations and Epigenetics[J]. Hematol Oncol Clin North Am, 2020,34:511-521.
    [13] Bohl SR, Bullinger L, Rücker FG. Epigenetic therapy:azacytidine and decitabine in acute myeloid leukemia[J].Expert Rev Hematol, 2018,11:361-371.
    [14] Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm[J].N Engl J Med, 2019,380:1628-1637.
    [15] Khwaja R, Daly A, Wong M, et al. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm:a report of 3 cases[J]. Leuk Lymphoma,2016,57:2720-2722.
    [16] Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax[J]. Cancer Discov,2017,7:156-164.
    [17] Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm[J]. Leukemia,2020,34:3228-3241.
  • 加载中
计量
  • 文章访问数:  14
  • HTML全文浏览量:  4
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-12
  • 网络出版日期:  2021-09-17

目录

    /

    返回文章
    返回